keyword
MENU ▼
Read by QxMD icon Read
search

botulinum neurotoxin type A

keyword
https://www.readbyqxmd.com/read/28705271/molecular-and-epidemiological-characterization-of-infant-botulism-in-beijing-china
#1
Yin Ping Dong, Wei Wang, Tao Jiang, Jin Xu, Chun Hui Han, Shao Fei Yan, Séamus Fanning, Ying Li, Xiao Chen Ma, Di Zhang, Yao Zhao, Biao Zeng, Feng Qin Li
Laboratory-based pathogen isolation, identification, and toxicity determination were performed on samples from a suspected case of infant botulism. Mice injected with cultures generated from the enema sample and ingested Powered infant formula (PIF) presented typical signs of botulism. Antitoxins to polyvalent botulinum neurotoxins (BoNTs) and monovalent BoNT type B antitoxin had protective effects. Clostridium botulinum isolated from the enema and residual PIF samples were positive for type B toxin. Pulsed-field gel electrophoresis (PFGE) revealed that the two strains of C...
June 2017: Biomedical and Environmental Sciences: BES
https://www.readbyqxmd.com/read/28692343/pulsotype-diversity-of-clostridium-botulinum-strains-containing-serotypes-a-and-or-b-genes
#2
Jessica L Halpin, Lavin Joseph, Janet K Dykes, Loretta McCroskey, Elise Smith, Denise Toney, Steven Stroika, Kelley Hise, Susan Maslanka, Carolina Lúquez
Clostridium botulinum strains are prevalent in the environment and produce a potent neurotoxin that causes botulism, a rare but serious paralytic disease. In 2010, a national PulseNet database was established to curate C. botulinum pulsotypes and facilitate epidemiological investigations, particularly for serotypes A and B strains frequently associated with botulism cases in the United States. Between 2010 and 2014 we performed pulsed-field gel electrophoresis (PFGE) using a PulseNet protocol, uploaded the resulting PFGE patterns into a national database, and analyzed data according to PulseNet criteria (UPGMA clustering, Dice coefficient, 1...
July 10, 2017: Foodborne Pathogens and Disease
https://www.readbyqxmd.com/read/28685363/the-role-of-endoscopic-intra-gastric-botulinum-toxin-a-for-obesity-treatment
#3
REVIEW
Hadya Elshakh, Khalid El-Ejji, Shahrad Taheri
Obesity prevalence has been increasing with devastating health and economic consequences. Botulinum toxin type A (BTX-A), a neurotoxin, is used clinically for conditions characterized by prolonged muscular contraction. Its inhibitory effects on gastric smooth muscles, in theory, make it a potential agent for obesity treatment through delayed gastric emptying and increased satiety. This review aims to examine the evidence for the use of endoscopic BTX-A injection for treating obesity. The literature search identified 60 articles with 11 primary studies as relevant for the scope of the review...
July 6, 2017: Obesity Surgery
https://www.readbyqxmd.com/read/28684374/investigating-crispr-cas-systems-in-clostridium-botulinum-via-bioinformatics-tools
#4
Manica Negahdaripour, Navid Nezafat, Nasim Hajighahramani, Seyyed Soheil Rahmatabadi, Younes Ghasemi
The Clustered regularly interspaced short palindromic repeats (CRISPR) systems are a type of innate immunity found in some prokaryotes, which protect them against alien genetic elements by targeting foreign nucleic acids. Some other functions are also attributed to these systems. Clostridium botulinum bacteria produce botulinum neurotoxins (BoNT), one of the deadliest known toxins for humans and some animals. Food poisoning due to these bacteria is still a challenge in food industries. On the other hand, BoNT has been widely investigated for therapeutic applications including different muscle disorders...
July 3, 2017: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/28674381/engineered-botulinum-neurotoxin-b-with-improved-efficacy-for-targeting-human-receptors
#5
Liang Tao, Lisheng Peng, Ronnie P-A Berntsson, Sai Man Liu, SunHyun Park, Feifan Yu, Christopher Boone, Shilpa Palan, Matthew Beard, Pierre-Etienne Chabrier, Pål Stenmark, Johannes Krupp, Min Dong
Botulinum neurotoxin B is a Food and Drug Administration-approved therapeutic toxin. However, it has lower binding affinity toward the human version of its major receptor, synaptotagmin II (h-Syt II), compared to mouse Syt II, because of a residue difference. Increasing the binding affinity to h-Syt II may improve botulinum neurotoxin B's therapeutic efficacy and reduce adverse effects. Here we utilized the bacterial adenylate cyclase two-hybrid method and carried out a saturation mutagenesis screen in the Syt II-binding pocket of botulinum neurotoxin B...
July 3, 2017: Nature Communications
https://www.readbyqxmd.com/read/28614091/injectable-daxibotulinumtoxina-for-the-treatment-of-glabellar-lines-a-phase-2-randomized-dose-ranging-double-blind-multicenter-comparison-with-onabotulinumtoxina-and-placebo
#6
Jean Carruthers, Nowell Solish, Shannon Humphrey, Nathan Rosen, Channy Muhn, Vince Bertucci, Arthur Swift, Andrei Metelitsa, Roman G Rubio, Jacob Waugh, John Quiring, Gill Shears, Alastair Carruthers
BACKGROUND: Injectable daxibotulinumtoxinA (RT002) is an investigational botulinum toxin Type A in clinical development. It is formulated with a proprietary peptide and offers the potential of a longer acting neurotoxin therapy. OBJECTIVE: To compare the safety, efficacy, and duration of response of daxibotulinumtoxinA with onabotulinumtoxinA and placebo [www.clinicaltrials.gov NCT02303002]. METHODS: In this Phase 2, randomized, dose-ranging, parallel-group, double-blind, multicenter study, subjects with moderate or severe glabellar lines at maximum frown were randomly assigned to 20U, 40U, or 60U daxibotulinumtoxinA, 20U onabotulinumtoxinA, or placebo...
June 12, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28596838/botulinum-neurotoxins-serotypes-a-and-b-induce-paralysis-of-mouse-striated-and-smooth-muscles-with-different-potencies
#7
Jacquie Maignel-Ludop, Marion Huchet, Johannes Krupp
To address the scarcity of direct comparison of botulinum neurotoxin serotypes activity on smooth versus striatal muscle, we have studied the action of BoNT/A1 and BoNT/B1 on ex vivo preparations of both muscle types. We have set up and characterized a model of neurogenic contractions in the isolated mouse bladder, and used this model to explore the effects of the two serotypes on contractions evoked by electrical field stimulation. Both toxins were also tested in the mouse phrenic nerve hemidiaphragm assay, to compare their potency in smooth versus striated muscle...
February 2017: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28587791/evaluation-of-anti-botulinum-neurotoxin-single-domain-antibodies-with-additional-optimization-for-improved-production-and-stability
#8
Lisa C Shriver-Lake, Dan Zabetakis, Ellen R Goldman, George P Anderson
Botulinum neurotoxin (BoNT) is a highly potent and lethal toxin, which even in minute quantities can lead to death. BoNT occurs in seven well described serotypes, A-G, and it is critical to not only detect the presence of BoNT, but also to determine the serotype to which a person has been exposed, as the degree of toxicity and persistence of symptoms varies greatly between the various types. Recently, Conway et al. 2010 developed single domain antibodies (sdAb), the recombinant variable domains of heavy-chain-only antibodies derived from camelids, for the detection of all seven serotypes of BoNT; identifying pairs of sdAb for each serotype they demonstrated the sensitive detection of each toxin...
June 3, 2017: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/28584101/deubiquitinating-enzyme-vcip135-dictates-the-duration-of-botulinum-neurotoxin-type-a-intoxication
#9
Yien Che Tsai, Archana Kotiya, Erkan Kiris, Mei Yang, Sina Bavari, Lino Tessarollo, George A Oyler, Allan M Weissman
Botulism is characterized by flaccid paralysis, which can be caused by intoxication with any of the seven known serotypes of botulinum neurotoxin (BoNT), all of which disrupt synaptic transmission by endoproteolytic cleavage of SNARE proteins. BoNT serotype A (BoNT/A) has the most prolonged or persistent effects, which can last several months, and exerts its effects by specifically cleaving and inactivating SNAP25. A major factor contributing to the persistence of intoxication is the long half-life of the catalytic light chain, which remains enzymatically active months after entry into cells...
June 27, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28566161/long-term-safety-of-repeated-high-doses-of-incobotulinumtoxina-injections-for-the-treatment-of-upper-and-lower-limb-spasticity-after-stroke
#10
Andrea Santamato, Francesco Panza, Domenico Intiso, Alessio Baricich, Alessandro Picelli, Nicola Smania, Francesca Fortunato, Davide Seripa, Pietro Fiore, Maurizio Ranieri
Current guidelines suggested a dosage up to 600units (U) of botulinum toxin type A (BoNT-A) (onabotulinumtoxinA or incobotulinumtoxinA) in reducing spastic hypertonia with low prevalence of complications, although a growing body of evidence showed efficacy with the use of high doses (>800U). The available evidence mainly referred to a single set of injections evaluating the efficacy and safety of the neurotoxin 30days after the treatment. In a prospective, non-randomized, open-label study, we studied the safety of repeated higher doses of incobotulinumtoxinA in post-stroke upper and lower limb spasticity...
July 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28556093/recovery-of-rat-muscle-size-but-not-function-more-than-1-year-after-a-single-botulinum-toxin-injection
#11
Samuel R Ward, Viviane B Minamoto, Kentaro P Suzuki, Jonah B Hulst, Shannon N Bremner, Richard L Lieber
INTRODUCTION: Neurotoxin injection is used to treat a wide variety of neuromuscular disorders. The purpose of this study was to measure the functional and structural properties of botulinum toxin-injected adult rat skeletal muscle over nearly the entire lifespan. METHODS: Ten groups of animals were subjected to either neurotoxin injection [Botox, Type A (BT-A); Allergan, Irvine, California] or saline solution injection. Neurotoxin-injected animals (n = 90) were analyzed at different time-points: 1 week; 1 month; 3 months; 6 months; 12 months; or 18 months...
May 26, 2017: Muscle & Nerve
https://www.readbyqxmd.com/read/28546483/finished-whole-genome-sequences-of-two-clostridium-botulinum-type-a-b-isolates
#12
Jessica L Halpin, Karen Hill, Shannon L Johnson, David Carlton Bruce, T Brian Shirey, Janet K Dykes, Carolina Lúquez
Clostridium botulinum secretes a potent neurotoxin that causes devastating effects when ingested, including paralysis and death if not treated. In the United States, some clinically significant strains produce toxin type A while also harboring a silent B gene. These are the first two closed genome sequences published for this subset.
May 25, 2017: Genome Announcements
https://www.readbyqxmd.com/read/28546482/finished-whole-genome-sequence-of-clostridium-argentinense-producing-botulinum-neurotoxin-type-g
#13
Jessica L Halpin, Karen Hill, Shannon L Johnson, David Carlton Bruce, T Brian Shirey, Janet K Dykes, Carolina Lúquez
Here, we present a closed genome sequence for Clostridium argentinense strain 89G, the first strain identified to produce botulinum neurotoxin type G (BoNT/G). Although discovered in 1970, to date, there have been no reference quality sequences publicly available for this species.
May 25, 2017: Genome Announcements
https://www.readbyqxmd.com/read/28537692/long-term-response-of-different-botulinum-toxins-in-refractory-neurogenic-detrusor-overactivity-due-to-spinal-cord-injury
#14
Giuseppe Lombardi, Stefania Musco, Giovanni Bacci, Maria Celso, Valerio Bellio, Giulio Del Popolo
PURPOSE: To assess the response in spinal cord injured patients alternatively treated with different types and dosages of Botulinum neurotoxin type A (BoNT/A) over 15 years. MATERIAL AND METHODS: Patients who underwent first BoNT/A from 1999-2001 and practiced intermittent catheterization were included. Baseline 3-day bladder diary (BD) and urodynamics were collected. BoNT/A failure was defined when patients asked for re-injection ≤ 3 months post-treatment. Criteria for re-injection was at least one daily episode of urinary incontinence at BD...
May 23, 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/28522711/draft-genome-sequences-of-five-brazilian-clostridium-botulinum-group-iii-type-d-c-strains
#15
Cédric Woudstra, Roseane B Brito, Antônio A Fonseca Júnior, Rodrigo O S Silva, Francisco C F Lobato, Patrick Fach
Animal botulism is mainly associated with Clostridium botulinum group III-producing neurotoxin types C, C/D, D, and D/C. In this report, we present the draft genome sequences of the first five strains of Clostridium botulinum type D/C isolated in Brazil and used for vaccination purposes.
May 18, 2017: Genome Announcements
https://www.readbyqxmd.com/read/28522038/injectable-and-topical-neurotoxins-in-dermatology-basic-science-anatomy-and-therapeutic-agents
#16
REVIEW
Cerrene N Giordano, Seth L Matarasso, David M Ozog
Botulinum toxin is a potentially deadly anaerobic bacterial toxin that acts by inhibiting release of acetylcholine at the neuromuscular junction, thereby inhibiting contraction of the exposed striated muscle. There are currently 4 botulinum toxin preparations approved by the US Food and Drug Administration (FDA): onabotulinumtoxin, abobotulinumtoxin, incobotulinumtoxin and rimabotulinumtoxin. While significant overlap exists, each product has unique properties and specifications, including dosing, diffusion, and storage...
June 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28491822/comparison-of-the-expression-changes-after-botulinum-toxin-type-a-and-minocycline-administration-in-lipopolysaccharide-stimulated-rat-microglial-and-astroglial-cultures
#17
Anna Piotrowska, Katarzyna Popiolek-Barczyk, Flaminia Pavone, Joanna Mika
Botulinum neurotoxin type A (BoNT/A) and minocycline are potent drugs used in clinical therapies. The primary molecular mechanism of BoNT/A is the cleavage of SNARE proteins, which prevents cells from releasing neurotransmitters from vesicles, while the effects of minocycline are related to the inhibition of p38 activation. Both BoNT/A and minocycline exhibit analgesic effects, however, their direct impact on glial cells is not fully known. Therefore, the aim of the present study was to determine the effects of those drugs on microglial and astroglial activity after lipopolysaccharide (LPS) stimulation and their potential synergistic action...
2017: Frontiers in Cellular and Infection Microbiology
https://www.readbyqxmd.com/read/28458568/cost-effectiveness-analysis-of-abobotulinumtoxina-for-the-treatment-of-cervical-dystonia-in-the-united-kingdom
#18
Madhusubramanian Muthukumar, Kamal Desai, Seye Abogunrin, Timothy Harrower, Sylvie Gabriel, Jerome Dinet
BACKGROUND: Cervical dystonia (CD) involves painful involuntary contraction of the neck and shoulder muscles and abnormal posture in middle-aged adults. Botulinum neurotoxin type A (BoNT-A) is effective in treating CD but little is known about its associated cost-effectiveness. OBJECTIVE: To evaluate the cost-effectiveness of abobotulinumtoxinA for treating CD from the UK payer perspective. METHODS: A Markov model was developed to evaluate the cost-effectiveness of abobotulinum-toxinA versus best supportive care (BSC) in CD, with a lifetime horizon and health states for response, nonresponse, secondary nonresponse, and BSC in patients with CD (mean age: 53 years; 37% male)...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28455330/regulation-of-botulinum-neurotoxin-synthesis-and-toxin-complex-formation-by-arginine-and-glucose-in-clostridium-botulinum-atcc-3502
#19
Chase M Fredrick, Guangyun Lin, Eric A Johnson
Botulinum neurotoxin (BoNT), produced by neurotoxigenic clostridia, is the most potent biological toxin known and the causative agent of the paralytic disease botulism. The nutritional, environmental, and genetic regulation of BoNT synthesis, activation, stability, and toxin complex (TC) formation is not well studied. Previous studies indicated that growth and BoNT formation were affected by arginine and glucose in Clostridium botulinum types A and B. In the present study, C. botulinum ATCC 3502 was grown in toxin production medium (TPM) with different levels of arginine and glucose and of three products of arginine metabolism, citrulline, proline, and ornithine...
July 1, 2017: Applied and Environmental Microbiology
https://www.readbyqxmd.com/read/28450105/optimization-of-snap-25-derived-peptide-substrate-for-improved-detection-of-botulinum-a-in-the-endopep-ms-assay
#20
Osnat Rosen, Liron Feldberg, Eyal Dor, Sigalit Gura, Ran Zichel
Botulinum neurotoxins (BoNTs) are the most toxic proteins in nature. Endopeptidase-mass-spectrometry (Endopep-MS) is used as a specific and rapid in-vitro assay to detect BoNTs. In this assay, immunocaptured toxin cleaves a serotype-specific-peptide-substrate, and the cleavage products are then detected by MS. Here we describe the design of a new peptide substrate for improved detection of BoNT type A (BoNT/A). Our strategy was based on reported BoNT/A-SNAP-25 interactions integrated with analysis method efficiency considerations...
July 1, 2017: Analytical Biochemistry
keyword
keyword
95792
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"